Assessment of the Association Between Visceral Obesity and the Progression of Diabetic Nephropathy

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06563791

Enrollment

100

Registered

2024-08-21

Start date

2024-09-30

Completion date

2025-10-31

Last updated

2024-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathies

Brief summary

Assessment of the association between visceral obesity and the progression of diabetic nephropathy

Detailed description

Type 2 diabetes mellitus is a disorder of diverse aetiology characterised by hyperglycemia resulting from abnormalities of insulin action, insulin production, or both, and the global population with diabetes mellitus is expected to be around 439 million by 2030 . Diabetic nephropathy is the most prevalent microvascular consequence of DM. It develops in around 40% of DM patients. Obesity, which has now reached pandemic ratios, is frequently accompanied by diabetes mellitus type 2 because they share common pathophysiological pathways . Abdominal obesity is found to be a negligent form of obesity with dangerous consequences. It has been identified as potentially hazardous factor for diabetic complications. Several abdominal obesity measures have been developed including the visceral adiposity index (VAI) , lipid accumulation product (LAP) , neck circumference (NC), waist-to-hip ratio (WHR) Lipid accumulation product (LAP) and visceral adiposity index (VAI) are new, non-imaging indicators of visceral adiposity measured using body mass index (BMI), waist circumference (WC), and serum lipid profile. It was predicted in some studies that LAP and VAI have a stronger association with poor renal outcomes than BMI and WC.

Interventions

None listed

Study design

Observational model

CASE_CROSSOVER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

\- 1. Diabetic patients either type 1 or type 2 diabetes aged \> 18 years whether known to have diabetic nephropathy or not. 2\. BMI is ≥ 25 kg/m2

Exclusion criteria

* 1\. Patients age \< 18 years. 2. BMI \< 25 kg/m2 3. Nondiabetic patients 4. Patients with non-diabetic kidney disease. 5. Patients with AKI 6. Patients with CKD stage 5 either on dialysis or not.

Design outcomes

Primary

Measure	Time frame	Description
Assessment of the association between visceral obesity and the progression of diabetic nephropathy	Baseline	Assessment of visceral obesity new measures as (the visceral adiposity index (VAI) , lipid accumulation product (LAP) , neck circumference (NC), waist-to-hip ratio (WHR) ) as a risk factor for the progression of diabetic nephropathy and poor renal outcome.

Contacts

Primary ContactNourhan Mohamed Ehab

mohamedehabahmed204@gmail.com+201062839349

Backup ContactRadwa awad

Outcome results